Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://branchh528lcs3.blog5star.com/profile